Pages that link to "Q39006105"
The following pages link to Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus (Q39006105):
Displaying 7 items.
- Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes (Q37620904) (← links)
- Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use. (Q39164190) (← links)
- Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus (Q47594318) (← links)
- A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes (Q47766606) (← links)
- Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study. (Q48264817) (← links)
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial (Q57471302) (← links)
- Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice (Q57822732) (← links)